Danirixin
- Generic Name
- Danirixin
- Drug Type
- Small Molecule
- Chemical Formula
- C19H21ClFN3O4S
- CAS Number
- 954126-98-8
- Unique Ingredient Identifier
- R318PGH5VP
- Background
Danirixin has been used in trials studying the treatment and basic science of Virus Diseases, Nutritional Status, Pulmonary Disease, Chronic Obstructive, and Infections, Respiratory Syncytial Virus.
GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT03457727
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 19
- Registration Number
- NCT03250689
- Locations
- π¬π§
GSK Investigational Site, Dundee, United Kingdom
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: PlaceboDevice: Metered dose inhaler (MDI) sensor deviceDrug: Rescue medication
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT03170232
- Locations
- πΊπΈ
GSK Investigational Site, Houston, Texas, United States
Study of Danirixin in Japanese Healthy Elderly Male Subjects
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT03136380
- Locations
- π―π΅
GSK Investigational Site, Tokyo, Japan
Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 614
- Registration Number
- NCT03034967
- Locations
- πͺπΈ
GSK Investigational Site, Zaragoza, Spain
Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza
Phase 2
Terminated
- Conditions
- Virus Diseases
- Interventions
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT02927431
- Locations
- πΈπͺ
GSK Investigational Site, Lund, Sweden
A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT02453022
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression
Phase 1
Completed
- Conditions
- Infections, Respiratory Syncytial Virus
- Interventions
- Other: CXCL1
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT02201303
- Locations
- πΊπΈ
GSK Investigational Site, Syracuse, New York, United States
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 102
- Registration Number
- NCT02130193
- Locations
- π©πͺ
GSK Investigational Site, Berlin, Germany
A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is Reduced
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT01453478
- Locations
- π¬π§
GSK Investigational Site, Nottingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath